Hanall Biopharma stock reports 8.8 percent Q2 revenue growth

Published on 10/07/2026 at 01:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Hanall Biopharma stock reached KRW 443 billion in Q2 2026 revenue, with KRW 56 billion in operating profit. IBK Securities kept a Buy rating while cutting its target to KRW 70,000.

Hanall Biopharma, KR7009420001, Illustration mit AI erstellt.

Hanall Biopharma (ISIN KR7009420001) reported Q2 2026 revenue of KRW 443 billion, up 8.8 percent from a year earlier. The stock was last at KRW 47,800 on the Korea Exchange on October 6, 2026 at 3:30 p.m. KST, up 3.69 percent from the previous close.

Revenue grows while profit improves

According to ATS View, Hanall Biopharma generated KRW 443 billion in consolidated Q2 2026 revenue and KRW 56 billion in operating profit. The operating margin was 12.6 percent, compared with 2.1 percent on KRW 400 billion of revenue in Q1 2026.

The earnings profile still carries a sharp counterweight. ChosunBiz reported on September 27, 2026, that the company posted a consolidated Q2 net loss of KRW 19.2 billion after development costs linked to a partner program and arbitration expenses.

Pipeline setback shifts attention

The clinical setback concerned cutaneous lupus erythematosus, while Hanall Biopharma continued development in five other indications, including rheumatoid arthritis, Graves disease and Sjogren syndrome, according to ChosunBiz. That leaves the pipeline mix, rather than quarterly sales alone, as the key valuation variable.

Financial News reported on September 28, 2026, that IBK Securities maintained a Buy rating while cutting its target price from KRW 73,000 to KRW 70,000. The revised target lies 46.4 percent above the October 6 price of KRW 47,800.

Stock rises within yearly range

Hanall Biopharma shares traded between KRW 45,850 and KRW 48,750 during the October 6 session. The 52-week range was KRW 32,600 to KRW 73,000, placing the latest price 34.5 percent below the yearly high.

The company had a market capitalization of KRW 2.4 trillion and volume of 233,794 shares on October 6, 2026. For investors, the contrast is clear: Q2 revenue growth and operating profit provide operating support, while the clinical portfolio still sets the risk profile.